Targeted Alkaline Phosphatase Therapy Enhances Alveolar Bone Healing in X‐Linked Hypophosphatemia in Mice
Open Access
- 8 October 2025
- journal article
- Published by Wiley in Journal of Periodontal Research
- Vol. 61 (3) , 309-322
Abstract
Aim: X‐linked Hypophosphatemia (XLH), caused by PHEX mutations, hinders skeletal and dental mineralization and contributes to tooth loss. While XLH is associated with dental implant‐related complications, no clinical or preclinical studies have investigated socket healing. XLH secondarily disrupts local mineral metabolism by increasing levels of the mineralization inhibitors, osteopontin (OPN) and inorganic pyrophosphate (PP i ). Tissue‐nonspecific alkaline phosphatase (TNAP) promotes mineralization by dephosphorylating OPN and hydrolyzing PP i . In this proof‐of‐principle study, we hypothesized that alveolar bone socket healing defects in the Hyp mouse model of XLH would be improved by exogenous TNAP. Methods: Maxillary first molars were extracted from wild‐type (WT) and Hyp mice at 6 weeks, and collagen gel ± mineral‐targeted TNAP (TNAP‐Fc‐D 10 ; asfotase alfa) was placed in sockets. Submucosal injections of TNAP‐Fc‐D 10 or saline were delivered at 7 and 14 days post‐procedure (dpp) in some mice. Maxillae were collected at 21 dpp for micro‐computed tomography, histology, and RT‐qPCR. Results: Untreated Hyp mice showed impaired socket healing compared to WT mice in bone volume and density. TNAP delivered at the time of extraction was unable to improve healing in Hyp mice. However, additional local TNAP delivery increased both alveolar bone volume and density in Hyp mice. Histology indicated repeated TNAP increased both woven and mature bone in Hyp mouse sockets. Immunostaining for osteopontin and bone sialoprotein suggested partial resolution of osteoid accumulation. Conclusion: TNAP enhanced socket healing in Hyp mice, overcoming inherent bone healing defects in XLH. These results provide new insights into bone healing with implications beyond alveolar bone in XLH.Keywords
Funding Information
- National Institute of Dental and Craniofacial Research (R01DE032334)
- National Institute on Aging (P01AG081167)
This publication has 108 references indexed in Scilit:
- Burosumab and Dental Abscesses in Children With X‐Linked HypophosphatemiaJBMR Plus, 2022
- Guidelines for Micro–Computed Tomography Analysis of Rodent Dentoalveolar TissuesJBMR Plus, 2021
- Mineralization Defects in the Primary Dentition Associated With X‐Linked Hypophosphatemic RicketsJBMR Plus, 2021
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary AnalysisJournal of Bone and Mineral Research, 2018
- FGF23 Regulates Bone Mineralization in a 1,25(OH)2D3 and Klotho-Independent MannerJournal of Bone and Mineral Research, 2015
- Ablation of Osteopontin Improves the Skeletal Phenotype of Phospho1 −/− MiceJournal of Bone and Mineral Research, 2014
- In Vivo Overexpression of Tissue-Nonspecific Alkaline Phosphatase Increases Skeletal Mineralization and Affects the Phosphorylation Status of OsteopontinJournal of Bone and Mineral Research, 2013
- Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2012
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011
- Guidelines for assessment of bone microstructure in rodents using micro–computed tomographyJournal of Bone and Mineral Research, 2010